WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

GE HealthCare Technologies Inc. GEHC

NasdaqMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
GEHC financials
Moat score
81
ROIC
11.0%
P/E
17.6
EV/EBIT
15.6
FCF yield
5.0%
Dividend yield
0.2%
Market cap
$37.8B

Moat ranks

Score rankTied #134 of 396
Durabilitydurable
Market structureOligopoly
Pricing powermoderate

Balance sheet

9/30/26
$BDec 31Sep 30
Cash4.52.8
Securities0.00.0
Debt10.010.0
Net cash-5.5-7.1
Equity10.411.6
Leverage
Debt / EBITDA
2.84×
Debt / equity
0.86×
Capital
Diluted shares
453M
Book value / share
$25.64
Price / book
3.3×
Net cash / share
−$15.78
Market cap
$37.8B
Enterprise value
$45.0B

Per-share record

Fiscal years and TTM
Scale
$0$20$40$60'19'20'21'22'23'2445.03'2547.76TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q3 '26
IndicatorLatestVs year agoLast 8 quarters
Revenue growth7.2%+1.4 pts
Operating margin14.6%+1.9 pts
FCF margin14.4%+5.0 pts
Capex / revenue2.1%-0.1 pts
Organic orders growth+4%–
Book-to-bill1–
Order backlog$23.7B–
Service sales · 6/30/26$1.9B+8%
AIS revenue · 6/30/26$3.8B+8%

Margins and growth from reported quarters; company KPIs as reported in results releases.

About GEHC

GE HealthCare sells imaging systems, patient-care equipment and diagnostic drugs. Its latest recast quarter puts 71.3% of segment revenue in Advanced Imaging Solutions, 12.8% in Patient Care Solutions and 15.9% in Pharmaceutical Diagnostics.

Revenue mix
Advanced Imaging Solutions (AIS) 71.3%Pharmaceutical Diagnostics (PDx) 15.9%Patient Care Solutions (PCS) 12.8%
  • Service Field Network

    Large installed base supported by a global field service organization; uptime-critical assets drive service contract attachment and parts revenue.

  • Data Workflow Lockin

    Imaging software, AI applications, and data integration services embed GEHC into radiology workflows; lifecycle software upgrades reduce willingness to switch OEMs.

  • Scope Economies

    AIS combines radiology, specialized ultrasound and procedural guidance, allowing imaging, ultrasound and software capabilities to be reused across modalities and procedure-room offerings.

  • Installed Base Consumables

    Monitoring fleets drive recurring revenue via proprietary parameters, sensors, and a broad catalog of consumables and service contracts.

Timeline
  1. Oct 5, 2026

    GE HealthCare agreed to buy SOFIE for $945M cash, adding 15 US manufacturing sites and 21 cyclotrons if the transaction closes in the first half of 2027.

  2. Sep 23, 2026

    GE HealthCare expanded research with Mass General Brigham on generative AI for radiation-therapy planning, testing an extension of its clinical software capabilities without a commercial product approval.

  3. Sep 22, 2026

    GE HealthCare raised its quarterly dividend from $0.035 to $0.04 per share, increasing its regular shareholder payout while funding acquisitions.

  4. Sep 22, 2026

    GE HealthCare appointed Pascal Desroches to its board effective January 4, 2027, adding a finance executive during its acquisition and portfolio review program.

  5. Sep 15, 2026

    GE HealthCare launched CareIntellect for Operations with two first health-system adopters, extending its hospital workflow software portfolio.

Financial record

Fiscal year2019202020212022202320242025TTMTrendChange 2019–25
Per share ($)
Revenue––38.7340.4042.6942.8645.0347.76–
Cash flow––3.544.654.594.254.345.33–
Earnings––4.914.183.434.344.554.75–
Free cash flow––2.993.973.743.383.294.17–
Capex––0.550.680.840.871.051.16–
Dividends––0.000.000.090.120.140.14–
Book value––36.6920.6115.5718.4022.6625.64–
Diluted shares (M)––454454458459458453–
Totals ($B)
Revenue16.617.217.618.319.619.720.621.6+3.7%/yr
Operating income2.12.72.82.52.42.62.82.9+4.5%/yr
Net income1.72.02.21.91.62.02.12.2+3.9%/yr
Free cash flow1.71.41.41.81.71.61.51.9-1.6%/yr
Buybacks0.00.00.00.00.00.00.20.3–
Dividends0.00.00.00.00.00.10.10.1–
Net cash–1.00.5-6.8-6.9-6.1-5.5-7.1–
Margins & returns (%)
Gross margin39.439.440.839.140.541.740.039.9+0.6 pts
Operating margin12.815.815.913.812.513.313.413.3+0.6 pts
Net margin9.911.712.710.38.010.110.110.0+0.2 pts
FCF margin10.08.37.79.88.87.97.38.7-2.7 pts
ROIC–14.112.411.112.312.912.411.0–
Return on equity7.713.613.420.322.023.620.118.5+12.4 pts
R&D % of revenue5.04.74.65.66.26.76.16.1+1.1 pts
Stock pay % of revenue0.40.50.40.40.60.60.60.7+0.2 pts
Capex % of revenue2.01.51.41.72.02.02.32.4+0.3 pts

Change uses 2019 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2019 base. Trend shows the fiscal years.

TTM = four quarters to Sep 30, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 28.7% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score81
Strength
Confidence
Structure
Oligopoly
Durability
durable
Trajectory
stable
Pricing power
moderate
Segments
  • Advanced Imaging Solutions (AIS)71.3%
    3 claims
  • Patient Care Solutions (PCS)12.8%
    2 claims
  • Pharmaceutical Diagnostics (PDx)15.9%
    3 claims

Moat claims

Applies to
Advanced Imaging Solutions (AIS)
Confidence
Durability
durable
Trajectory
stableas of Oct 8, 2026
Why it holds

Large installed base supported by a global field service organization; uptime-critical assets drive service contract attachment and parts revenue.

Why stable

First-half service sales rose 7.6%, but acquisitions contributed and service renewal rates are not disclosed; the service footprint remains a durable advantage.

Indicators
  • Organic orders growth+4%
  • Book-to-bill1
  • Order backlog$23.7B
  • Service sales$1.9B+8%
  • AIS revenue$3.8B+8%
  • AIS segment EBIT$525M+15%
  • Field service engineers~8,900+7%
Risks
  • Right-to-repair regulations expanding third-party access
  • Independent service organizations (ISOs) undercut OEM service pricing
  • Increased remote diagnostics reducing differentiation of onsite service

Profile change log

  1. Oct 9, 2026 · analyst revision

    Clarified the July 29 AIS event as the first combined segment-results disclosure. The segment combination itself was announced on April 29, so its announcement now has a separate dated event.

  2. Oct 9, 2026 · business change

    GE HealthCare announced that Imaging and Advanced Visualization Solutions would combine into AIS, aligning imaging hardware and software under one segment; later quarterly disclosures recast the comparative figures.

  3. Oct 9, 2026 · analyst revision

    Added the disclosed but unquantified IRS tax-indemnity exposure to the investment debate. The resolved PDx supplier issue and contract-settlement income remain in reported earnings because separate amounts are not disclosed.

  4. Oct 9, 2026 · business change

    GE HealthCare expanded research with Mass General Brigham on generative AI for radiation-therapy planning, testing an extension of its clinical software capabilities without a commercial product approval.

  5. Oct 9, 2026 · business change

    GE HealthCare reduced 2026 adjusted EPS guidance from $4.95-$5.15 to $4.80-$5.00 as memory, oil and freight inflation increased, while keeping its organic revenue growth outlook.

  6. Oct 9, 2026 · analyst revision

    Changed the PDx supply trajectory from widening to stable because higher sales and pending capacity do not prove stronger supply protection. Added competitor operating evidence and legal and safety developments, restored sourced major suppliers without market-share estimates, and corrected the CFO board-appointment date from August 18 to August 13.

  7. Oct 9, 2026 · business change

    GE HealthCare appointed Pascal Desroches to its board effective January 4, 2027, adding a finance executive during its acquisition and portfolio review program.

  8. Oct 9, 2026 · business change

    GE HealthCare announced StarGuide GX SPECT/CT following CE Mark; US FDA clearance remains pending, so US commercial access is conditional.

  9. Oct 9, 2026 · business change

    Health Canada dated a Type II Centricity High Acuity Anesthesia recall for errors in order summaries and printed records, adding a clinical-software reliability risk.

  10. Oct 9, 2026 · business change

    GE HealthCare introduced three Vivid cardiovascular ultrasound systems, broadening cardiac imaging and procedural workflows across care settings.

  11. Oct 9, 2026 · business change

    GE HealthCare entities and other defendants asked the US Supreme Court to review the Atchley anti-terrorism case; the petition does not resolve the underlying claims or damages.

  12. Oct 9, 2026 · business change

    GE HealthCare bought icometrix for about $98M net cash plus possible earn-outs, adding brain-imaging software for integration with its MRI systems.

  13. Oct 9, 2026 · business change

    GE HealthCare committed $138M to expand its Cork contrast-agent factory, targeting 25 million additional annual doses by the end of 2027.

  14. Oct 9, 2026 · business change

    GE bought BK Medical for $1.466B, adding surgical ultrasound and guidance to the portfolio and explaining most of the 2021 acquisition cash outflow.

  15. Oct 8, 2026 · analyst revision

    Added all eight moat trajectories, segment end markets, operating KPI history, management and an investment debate. PCS advantages are narrowing under sourced fulfillment and software-reliability pressures; claim strengths and all profile timestamps stay unchanged. Removed unsupported full-market leaders and sizing from the shared imaging profile. Separation costs recur through 2026 and remain in reported earnings.

  16. Oct 8, 2026 · business change

    GE HealthCare agreed to buy SOFIE for $945M cash, adding 15 US manufacturing sites and 21 cyclotrons if the transaction closes in the first half of 2027.

  17. Oct 8, 2026 · business change

    GE HealthCare raised its quarterly dividend from $0.035 to $0.04 per share, increasing its regular shareholder payout while funding acquisitions.

  18. Oct 8, 2026 · business change

    GE HealthCare launched CareIntellect for Operations with two first health-system adopters, extending its hospital workflow software portfolio.

  19. Oct 8, 2026 · business change

    GE HealthCare received CE Mark for Photonova Spectra, expanding access to its photon-counting CT system in European markets.

  20. Oct 8, 2026 · business change

    FDA classified the Portrait software instruction correction as Class II; customers must provide alternative monitoring during software updates.

  21. Oct 8, 2026 · business change

    GE HealthCare's board appointed William Grogan as CFO effective September 14, placing a new finance leader in charge of cost control and acquisition funding; the company announced the appointment on August 18.

  22. Oct 8, 2026 · business change

    GE HealthCare issued a Centricity PACS data-migration correction because images could attach to the wrong patient, creating safety and workflow trust risks.

  23. Oct 8, 2026 · business change

    GE HealthCare published its first combined AIS segment results and announced a strategic review of PCS after a $26M quarterly loss, focusing capital allocation on its stronger businesses.

  24. Oct 8, 2026 · business change

    GE HealthCare bought Intelerad for $2.293B net cash, expanding outpatient imaging software and increasing acquired-intangible amortization.

  25. Oct 8, 2026 · business change

    GE HealthCare bought the remaining Nihon Medi-Physics stake for $271M net cash, expanding Japanese radiopharmaceutical production and recording a $97M stake remeasurement gain.

  26. Oct 8, 2026 · business change

    GE HealthCare became an independent listed company, assuming stand-alone costs, debt and transferred pension obligations.

  27. Oct 8, 2026 · business change

    GE sold its BioPharma business to Danaher, removing a business whose sale gain distorts historical consolidated earnings.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianGEHC
No peer numbers yet

Peers appear on the map as their numbers are collected.

Global diagnostic imaging and image-guided therapy

As of Oct 9, 2026
OligopolyMedium cyclicality

Global diagnostic imaging, specialized ultrasound and image-guided procedure systems, with related service, software and enterprise imaging workflows. Excludes general patient monitoring, diagnostic agents and standalone therapeutic radiation systems.

  1. GE HealthCare
  2. Siemens Healthineers
  3. Philips
  4. Canon
  5. United Imaging
2025 leaders, no comparable shares · GE HealthCare 2025 Form 10-K
StocksMoatGross m.Op. m.
GEHC8139.9%13.3%
Industry median147552.1%13.3%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Ageing populations and chronic disease increase diagnostic scans and minimally invasive procedures.
  • Hospital staff shortages raise demand for faster scans, remote servicing and integrated clinical workflows.
  • AI reconstruction, spectral CT and helium-free MRI can support replacement demand and premium product mix.
  • Hospital financing costs and public budgets control the timing of large equipment orders.
  • Insurance reimbursement for scans and procedures affects equipment utilization and the cash hospitals can reinvest.
Risks
  • Hospital tenders and strong GE HealthCare, Siemens, Canon and local competition constrain prices.
  • China purchasing delays and preference for domestic equipment can weaken multinational demand.
  • Tariffs, currency translation and scarce technical inputs can reduce profit even when comparable demand grows.
  • Patient-safety recalls, cybersecurity failures and strict approval rules can delay launches and damage service trust.
  • Open data standards and independent service firms reduce the value customers place on a single-vendor software or repair system.

Bulls & bears

Key question · as of Oct 9, 2026

Can imaging service and diagnostic-agent growth convert into cash and lasting profit while GE repairs PCS and integrates its software acquisitions?

Arguments

4 forFaded: weakening or settled6 against

What to watch

  1. 1Organic orders, backlog and AIS service revenue
  2. 2PCS revenue and segment EBIT after fulfillment recovery
  3. 3PDx organic revenue, operating cash flow and total debt

Next check: Q4 2026 results: test current customer demand, cash conversion, current guidance and material later management or regulatory events.

Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 81/100 by <a href="https://www.findmymoat.com/stocks/XNAS:GEHC">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.